• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket

    6/28/23 8:04:54 AM ET
    $AREB
    $ASTS
    $AVTX
    $BDRX
    Plastic Products
    Industrials
    Telecommunications Equipment
    Consumer Discretionary
    Get the next $AREB alert in real time by email

    Gainers

    • Theriva Biologics, Inc. (NYSE:TOVX) shares surged 76.4% to $1.46 in pre-market trading after the company said Orphan Drug Designation was granted by the U.S. Food and Drug Administration for VCN-01 for the treatment of pancreatic cancer.
    • iMedia Brands, Inc. (NASDAQ:IMBI) shares gained 55.1% to $0.2497 in pre-market trading after dropping over 15% on Tuesday. iMedia Brands recently announced receipt of second Nasdaq non-compliance notice.
    • National CineMedia, Inc. (NASDAQ:NCMI) shares rose 12.8% to $0.3525 in pre-market trading. National CineMedia said plan of reorganization has been confirmed by the United States Bankruptcy Court.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) rose 12.5% to $0.0805 in pre-market trading after jumping 14% on Tuesday. Biodexa Pharmaceuticals announced a 1 ADR for 400 ordinary share ratio change effective July 5, 2023.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares rose 12.1% to $0.6390 in pre-market trading after dropping more than 6% on Tuesday.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) shares gained 10.2% to $1.30 in pre-market trading. Cardio Diagnostics recently announced the nationwide launch of PrecisionCHD.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares climbed 9.7% to $0.4716 in pre-market trading after declining around 14% on Tuesday. Avalo Therapeutics recently announced its Phase 2 Peak trial For quisovalimab In patients With non-eosinophilic asthma missed its primary endpoint.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) rose 8.7% to $0.67 in pre-market trading.
    • Pasithea Therapeutics Corp. (NASDAQ:KTTA) gained 8.3% to $0.4980 in pre-market trading. Pasithea Therapeutics recently confirmed receipt of unsolicited proposal from Lucy Scientific Discovery.
    • Edgio, Inc. (NASDAQ:EGIO) gained 7.3% to $0.6490 in pre-market trading after declining 3% on Tuesday.

    Losers

    • AST SpaceMobile, Inc. (NASDAQ:ASTS) fell 22.6% to $4.93 in pre-market trading after the company reported pricing of upsized offering of Class A common stock.
    • Leafly Holdings, Inc. (NASDAQ:LFLY) fell 16.2% to $0.31 in pre-market. Leafly was granted U.S. patent #11687994 for "Systems For Selection Of Cannabis-Related Products And Visualization Of Chemical Data (The Decision Engine May Implement Artificial Intelligence)."
    • Lordstown Motors Corp. (NASDAQ:RIDE) fell 13.1% to $1.99 in pre-market trading. Lordstown Motors shares dropped 17% on Tuesday after the company opted to file for Chapter 11 bankruptcy protection.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) fell 9.9% to $0.1253 in pre-market trading. Tivic Health Systems shares gained 39% on Tuesday after the company announced that it entered into a non-exclusive distribution agreement with Cardinal Health.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) fell 8.7% to $5.02 in pre-market trading after jumping 17% on Tuesday. American Rebel recently announced a 1-for-25 reverse stock split.
    • Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) fell 7.2% to $0.2922 in pre-market trading after dropping around 8% on Tuesday.
    • Centogene N.V. (NASDAQ:CNTG) fell 6.8% to $1.10 in pre-market trading. CENTOGENE shares jumped over 50% on Tuesday after the company and Lifera formed a Saudi Arabian joint venture.
    • Siyata Mobile Inc. (NASDAQ:SYTA) shares dropped 6.7% to $0.0540 in pre-market trading. Siyata Mobile shares dipped around 35% on Tuesday after the company priced a 50 million share offering at $0.045 per share.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares dropped 6.3% to $0.2534 in pre-market trading after jumping 19% on Tuesday. Surgalign recently received NASDAQ delisting notice following its Chapter 11 filing.
    • Digital Media Solutions, Inc. (NYSE:DMS) shares fell 5% to $0.3376 in pre-market trading after dropping over 12% on Tuesday.

     

    Now Read This: Fear & Greed Index Moves To 'Extreme Greed' Zone After Dow Jumps Over 200 Points

    Get the next $AREB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREB
    $ASTS
    $AVTX
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    AST SpaceMobile Inc.
    $ASTS
    1/13/2026$105.00Buy → Neutral
    B. Riley Securities
    AST SpaceMobile Inc.
    $ASTS
    1/7/2026$45.60Sector Perform → Sector Underperform
    Scotiabank
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    AST SpaceMobile Inc.
    $ASTS
    11/24/2025$45.60Sector Underperform → Sector Perform
    Scotiabank
    National CineMedia Inc.
    $NCMI
    10/31/2025$7.00 → $6.50Outperform
    Barrington Research
    AST SpaceMobile Inc.
    $ASTS
    10/17/2025$60.00Overweight → Underweight
    Barclays
    AST SpaceMobile Inc.
    $ASTS
    10/7/2025Sector Perform → Sector Underperform
    Scotiabank
    More analyst ratings

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Larson Keith R bought $50,000 worth of shares (625 units at $80.00) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/29/25 6:00:02 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Director Larson Keith R bought $50,064 worth of shares (715 units at $70.02) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/17/25 6:00:10 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Director Larson Keith R bought $49,079 worth of shares (675 units at $72.71) (SEC Form 4)

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    12/10/25 6:00:21 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AREB
    $ASTS
    $AVTX
    $BDRX
    SEC Filings

    View All

    SEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs

    20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:09:45 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:00:06 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by National CineMedia Inc.

    144 - National CineMedia, Inc. (0001377630) (Subject)

    3/27/26 4:39:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Avellan Abel Antonio

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    3/26/26 7:00:04 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form 4 filed by Johnson Andrew Martin

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    3/26/26 7:00:06 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form 4 filed by Wisniewski Scott

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    3/26/26 7:00:05 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMERICAN REBEL HOLDINGS, INC. (NASDAQ: AREB; AREBW) PROVIDES STOCKHOLDER UPDATE FOLLOWING 1-FOR-100 REVERSE STOCK SPLIT, CURRENT COMMON SHARES OUTSTANDING TO 227,554 (POST REVERSE), AND DISCLOSES ADDITIONAL NASDAQ STAFF DETERMINATION

    Company includes excerpts from Nasdaq's March 23, 2026, Additional Staff Determination Letter, discloses post-reverse-split common shares outstanding to 227,554, and reiterates belief that pending DTC/CEDE stockholder-beneficial fractional and round-lot top-up processing should restore compliance with Nasdaq's minimum publicly held shares requirement NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ:AREB, AREBW)) ("American Rebel" or the "Company") today provided stockholders with an update following the effectiveness of its 1-for-100 reverse stock split of its common stock and publicly traded warrants on March 23, 2026. This press release is also

    3/24/26 9:30:00 AM ET
    $AREB
    Plastic Products
    Industrials

    Nasdaq Halts American Rebel Holdings, Inc.

    NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading is halted in American Rebel Holdings, Inc. (NASDAQ:AREB) for additional information requested from the company. Previously, Nasdaq halted AREB at 19:50:00 on March 20, 2026 in connection with a previously announced reverse stock split. The last sale price of the company's shares was $0.0646.  Trading will remain halted until American Rebel Holdings, Inc. has fully satisfied Nasdaq's request for additional information. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web si

    3/23/26 9:00:00 AM ET
    $AREB
    $NDAQ
    Plastic Products
    Industrials
    Investment Bankers/Brokers/Service
    Finance

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AST SpaceMobile downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded AST SpaceMobile from Buy to Neutral and set a new price target of $105.00

    1/13/26 9:00:28 AM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    AST SpaceMobile downgraded by Scotiabank with a new price target

    Scotiabank downgraded AST SpaceMobile from Sector Perform to Sector Underperform and set a new price target of $45.60

    1/7/26 8:53:24 AM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Financials

    Live finance-specific insights

    View All

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AST SpaceMobile Provides Business Update and Fourth Quarter and Full Year 2025 Results

    Reported revenue of $70.9 million for the full year 2025, driven by mobile network operator partners and the U.S. Government Secured over $1.2 billion in aggregate contracted revenue commitments from partners Successfully completed unfolding of BlueBird 6, the largest commercial communications array ever deployed in low Earth orbit, expected to greatly exceed 120 Mbps peak data speeds Continued orbital launch campaign with encapsulation of BlueBird 7 at Cape Canaveral in February and expected launch during March, with additional launches expected every one to two months on average to reach goal of 45 to 60 satellites in orbit by end of 2026 AST SpaceMobile, Inc. ("AST SpaceMobile")

    3/2/26 4:32:00 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AREB
    $ASTS
    $AVTX
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AST SpaceMobile Inc.

    SC 13D/A - AST SpaceMobile, Inc. (0001780312) (Subject)

    11/20/24 9:59:14 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by National CineMedia Inc.

    SC 13D/A - National CineMedia, Inc. (0001377630) (Subject)

    11/20/24 9:34:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care